Stance Capital LLC Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Stance Capital LLC reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 94.3% during the 4th quarter, Holdings Channel reports. The fund owned 400 shares of the company’s stock after selling 6,587 shares during the quarter. Stance Capital LLC’s holdings in IDEXX Laboratories were worth $271,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC grew its stake in IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares in the last quarter. Harbour Investments Inc. raised its position in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after purchasing an additional 16 shares in the last quarter. CWA Asset Management Group LLC raised its position in IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after purchasing an additional 17 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its stake in shares of IDEXX Laboratories by 11.5% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after buying an additional 18 shares during the period. Finally, Rockland Trust Co. boosted its stake in shares of IDEXX Laboratories by 4.4% in the 4th quarter. Rockland Trust Co. now owns 425 shares of the company’s stock valued at $288,000 after buying an additional 18 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $562.09 on Monday. The stock has a 50-day simple moving average of $561.66 and a 200-day simple moving average of $620.14. The stock has a market cap of $44.34 billion, a P/E ratio of 41.39, a P/E/G ratio of 3.07 and a beta of 1.56. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the business posted $2.91 EPS. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on IDXX shares. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. UBS Group reduced their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Finally, Citigroup began coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.